Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice
- PMID: 1398912
- PMCID: PMC257429
- DOI: 10.1128/iai.60.10.4003-4008.1992
Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice
Abstract
We administered a neutralizing monoclonal antibody to tumor necrosis factor (TNF) during infection with Candida albicans in normal and granulocytopenic mice. Mice were rendered granulocytopenic (less than 0.1 x 10(9) granulocytes per liter) with cyclophosphamide. Growth of C. albicans from the kidneys was significantly increased in normal mice treated with the antibody to TNF, compared with that in control mice, after 36 h (3.6 x 10(4) +/- 1.2 x 10(4) CFU per kidney versus 9.1 x 10(3) +/- 6.2 x 10(3) CFU per kidney; P less than 0.05) and after 72 h (3.7 x 10(6) +/- 2.7 x 10(6) CFU per kidney versus 2.3 x 10(4) +/- 1.3 x 10(4) CFU per kidney; P less than 0.01). In granulocytopenic mice, the antibody to TNF had no effect on the growth of C. albicans from the kidneys. Furthermore, our study showed that the cytokines TNF and interleukin-6 (IL-6) were produced in a dose-dependent manner during C. albicans infection. TNF was detectable between 6 and 60 h, with peak levels at 24 h. Both TNF and IL-6 levels were significantly higher in cyclophosphamide-treated mice than in normal mice. Heat-inactivated C. albicans induced a TNF response different from that induced by viable C. albicans, with an early peak occurring at 3 to 4 h and declining to non-detectable levels after 15 to 24 h. Peak levels of TNF obtained with heat-inactivated C. albicans were lower than those obtained with viable C. albicans. Our study demonstrates that TNF and IL-6 are produced systemically during C. albicans infection and suggests that TNF is essential for granulocyte antifungal activity in vivo.
Similar articles
-
Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.Antimicrob Agents Chemother. 1993 Apr;37(4):729-36. doi: 10.1128/AAC.37.4.729. Antimicrob Agents Chemother. 1993. PMID: 8494367 Free PMC article.
-
Production of tumor necrosis factor-alpha in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor.Microbiol Immunol. 1995;39(6):411-7. doi: 10.1111/j.1348-0421.1995.tb02221.x. Microbiol Immunol. 1995. PMID: 8551973
-
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.Infect Immun. 2001 Aug;69(8):5046-55. doi: 10.1128/IAI.69.8.5046-5055.2001. Infect Immun. 2001. PMID: 11447185 Free PMC article.
-
Effects of stem cell factor and granulocyte colony-stimulating factor on granulocyte recovery and Candida albicans infection in granulocytopenic mice.J Infect Dis. 1993 Dec;168(6):1444-8. doi: 10.1093/infdis/168.6.1444. J Infect Dis. 1993. PMID: 7504035
-
Cytokine mediators of septic infections in the normal and granulocytopenic host.Eur J Haematol. 1993 May;50(5):243-9. doi: 10.1111/j.1600-0609.1993.tb00156.x. Eur J Haematol. 1993. PMID: 8319784 Review.
Cited by
-
In vitro and in vivo Characterization of Host-Pathogen Interactions of the L3881 Candida albicans Clinical Isolate.Front Microbiol. 2022 Jul 11;13:901442. doi: 10.3389/fmicb.2022.901442. eCollection 2022. Front Microbiol. 2022. PMID: 35898912 Free PMC article.
-
Trends in immunotherapy of fungal infections.Eur J Clin Microbiol Infect Dis. 1997 Jan;16(1):51-5. doi: 10.1007/BF01575121. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9063674 Review.
-
The Candida albicans phospholipomannan induces in vitro production of tumour necrosis factor-alpha from human and murine macrophages.Immunology. 1994 Oct;83(2):268-73. Immunology. 1994. PMID: 7835946 Free PMC article.
-
Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal Meningitis.Open Forum Infect Dis. 2025 Apr 2;12(4):ofaf190. doi: 10.1093/ofid/ofaf190. eCollection 2025 Apr. Open Forum Infect Dis. 2025. PMID: 40271162 Free PMC article.
-
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.Br J Pharmacol. 2012 Jun;166(3):806-22. doi: 10.1111/j.1476-5381.2011.01812.x. Br J Pharmacol. 2012. PMID: 22168335 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical